Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.64 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062901 | 0.89 | MAPT (0.67) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL28133927 | 0.88 | MAPT (0.70) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL14096572 | 0.87 | MAPT (0.68) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL2060705 | 0.86 | NR1H4 (0.73) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL2721612 | 0.84 | MAPT (0.73) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL2362772 | 0.84 | KMT2A (0.82) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL13310256 | 0.84 | MAPT (0.62) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL9645453 | 0.83 | ALDH1A1 (0.81) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL14435720 | 0.83 | MAPT (0.64) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL4347151 | 0.83 | MAPT (0.64) | MAPTSMN1; SMN2RAB9ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-20130310351-A1 | Treating Long QT Syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012054718-A2 | TREATING LONG QT SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| US-7727558-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | EMISPHERE TECHNOLOGIES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7208483-B2 | Polymeric delivery agents and delivery agent compounds | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310351-A1 | Treating Long QT Syndrome | TNNI3, TNNT2, TNNC1 | MAPT 3780/4885SMN1; SMN2 546/4885RAB9A 1007/4885 |
| US-20070141022-A1 | POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS | LPXN, PGF, TTPA | MAPT 853/4885SMN1; SMN2 1040/4885RAB9A 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.